| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/21/2009 | CA2356263C Aminopyrazole derivatives |
| 04/21/2009 | CA2272963C Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whiteningand/or cleaning of an individual's teeth |
| 04/21/2009 | CA2231603C Chicken interleukin-15 and uses thereof |
| 04/21/2009 | CA2193641C 66 kda antigen from borrelia |
| 04/21/2009 | CA2115927C Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus |
| 04/16/2009 | WO2009049208A1 Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| 04/16/2009 | WO2009049138A1 Cytomegalovirus vaccines and methods of production |
| 04/16/2009 | WO2009049013A2 Cholera vaccines |
| 04/16/2009 | WO2009048868A1 Photodynamic therapy process and photosensitizer compositions |
| 04/16/2009 | WO2009048841A1 Antifungal treatment of nails |
| 04/16/2009 | WO2009048839A2 Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| 04/16/2009 | WO2009048769A2 Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| 04/16/2009 | WO2009048607A1 Vaccine delivery via microneedle arrays |
| 04/16/2009 | WO2009048289A2 Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid |
| 04/16/2009 | WO2009047801A1 Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
| 04/16/2009 | WO2009047537A1 Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 04/16/2009 | WO2009047534A2 Fused phenothiazinium compounds, preparation method thereof and use as photoantimicrobials |
| 04/16/2009 | WO2009047363A1 Pharmaceuticals compositions comprising actinomycete glycerol acyl derivatives antigens, their process of extraction, and their use against tuberculosis |
| 04/16/2009 | WO2009047264A1 Spiropyrrolidines and their use against hcv and hiv infection |
| 04/16/2009 | WO2009046881A1 Use of a peptide combination including c-peptide, as a therapeutic agent |
| 04/16/2009 | WO2009046880A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046879A2 Use of the combination of npy and nociceptin as a therapeutic agent |
| 04/16/2009 | WO2009046878A1 Tnf inhibitory peptide and cgrp as therapeutic agents |
| 04/16/2009 | WO2009046877A2 Use of a histrelin and leuprolide as therapeutic agents |
| 04/16/2009 | WO2009046876A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046875A2 Combination of splenopentin and thymopentin and the use thereof in medicine |
| 04/16/2009 | WO2009046874A1 Therapeutic combination of trh-potentiating peptide and stresscopin |
| 04/16/2009 | WO2009046873A1 Combined use of vasonatrin and gastrin-i as a therapeutic agent |
| 04/16/2009 | WO2009046872A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046868A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046867A2 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 04/16/2009 | WO2009046866A2 Trap-14 as a therapeutic agent |
| 04/16/2009 | WO2009046865A2 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 04/16/2009 | WO2009046864A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046863A2 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046862A1 Use of physalemin as a therapeutic agent |
| 04/16/2009 | WO2009046861A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | WO2009046860A2 Use of dago as a therapeutic agent |
| 04/16/2009 | WO2009046859A2 Use of af12198 and dago as therapeutic agents |
| 04/16/2009 | WO2009046858A2 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 04/16/2009 | WO2009046857A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046856A2 Use of serorphin as a therapeutic agent |
| 04/16/2009 | WO2009046853A1 Use of intermedin 47 peptide as a therapeutic agent |
| 04/16/2009 | WO2009046852A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | WO2009046851A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046849A1 Use of the peptide cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046848A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046847A2 Use of peptide ll-37 as a therapeutic agent |
| 04/16/2009 | WO2009046846A2 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 04/16/2009 | WO2009046845A2 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 04/16/2009 | WO2009046844A1 Therapeutic uses of peptide tdvngdgrhdl |
| 04/16/2009 | WO2009046843A1 Therapeutic uses of peptides kvlpvpq and/or tdvngdgrhdl |
| 04/16/2009 | WO2009046834A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/16/2009 | WO2009046833A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046832A2 Short peptides used in medicine |
| 04/16/2009 | WO2009046831A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046830A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046829A2 Casoxin d as a therapeutic agent |
| 04/16/2009 | WO2009046827A2 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents |
| 04/16/2009 | WO2009046826A1 Use of a cyclic penta-peptide as a therapeutic agent |
| 04/16/2009 | WO2009046825A1 Use of a peptide acetyl-calpastatin as a therapeutic agent |
| 04/16/2009 | WO2009046824A2 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis |
| 04/16/2009 | WO2009046823A1 Exendin-3 and apelin-12 for therapeutic applications |
| 04/16/2009 | WO2009046822A2 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 04/16/2009 | WO2009046618A1 Deshydroxy vancomycin, the preparation, pharmaceutical composition and the use |
| 04/16/2009 | WO2009046573A1 Liver targeting adefovir prodrug and its medical use |
| 04/16/2009 | WO2009046536A1 Halogenated quinazolinyl nitrofurans as antibacterial agents |
| 04/16/2009 | WO2009046497A1 Method of eliciting an immune response against pandemic influenza virus |
| 04/16/2009 | WO2009026348A3 Antifungal agents from a streptomycete |
| 04/16/2009 | WO2009026306A3 Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| 04/16/2009 | WO2009002652A3 Use of surfactants for treating mycobacterial infections |
| 04/16/2009 | WO2008124571A3 Anti-viral compounds, compositions and methods |
| 04/16/2009 | WO2008115707A3 Post-exposure prophylaxis and treatment of infections caused by anthrax |
| 04/16/2009 | WO2008067982A3 Use of carrageenan for treating rhinovirus infections |
| 04/16/2009 | WO2008043840A3 Anti-infective thiourea compounds |
| 04/16/2009 | US20090099373 Compositions enriched in anthocyanins |
| 04/16/2009 | US20090099202 External Preparation for Athlete's Foot Treatment |
| 04/16/2009 | US20090099194 CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders |
| 04/16/2009 | US20090099188 Microbicidal composition based on formaldehyde donor compounds and antioxidants |
| 04/16/2009 | US20090099168 HIV Integrase inhibitors |
| 04/16/2009 | US20090099161 Substituted Imidazoquinolines and Imidazonaphthyridines |
| 04/16/2009 | US20090099154 Pharmaceutical Sustained Release Compositions and Processes Thereof |
| 04/16/2009 | US20090099139 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 04/16/2009 | US20090099136 Dioxolane thymine phosphoramidates as anti-hiv agents |
| 04/16/2009 | US20090099126 2'-C-(methyl-),2'-O-,3'-O-(benzylidene)<)adenosine; hepatitus C virus prodrugs ofpolymerase enzyme inhibitors; inhibition of HCV NS5B polymerase prevents formation ofthe double-stranded Hepitis C virus RNA; replication-defecctive; viral infections; Flaviviruses; picornavirus; rhinovirus; polio virus |
| 04/16/2009 | US20090099124 Short interfering rna as an antiviral agent for hepatitis c |
| 04/16/2009 | US20090099110 Antiviral oligonucleotides |
| 04/16/2009 | US20090099105 Content dependent inhibitors of cytidine deaminases and uses thereof |
| 04/16/2009 | US20090099096 HIV proteases as therapeutic agents for inhibition and treatment of HIV infection in humans, administered in combination with other classes of HIV therapeutic agents, especially inhibitors of HIV reverse transcriptase |
| 04/16/2009 | US20090098636 Fungal cell wall synthesis gene |
| 04/16/2009 | US20090098544 Marker molecules associated with lung tumors |
| 04/16/2009 | US20090098528 Method for determining early HCV seroconversion |
| 04/16/2009 | US20090098227 Tto-based wide spectrum therapeutics, disinfectants & anesthetics for use in aquaculutre |
| 04/16/2009 | US20090098200 Compositions comprising lipophilic active compounds and method for their preparation |
| 04/16/2009 | US20090098195 Influenza virus infection suppressor |
| 04/16/2009 | US20090098194 Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same |
| 04/16/2009 | US20090098161 removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition and to impair Complement Factor H binding, CD55 and CD59 removal prevent the binding of Complement Factor H; Acquired Immunodeficiency Syndrome |
| 04/16/2009 | US20090098158 Porcine cirocvirus type 2 (PCV2); Actinobacillus pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyrhinis, Mycoplasma hyopneumoniae, Pasteurella multocida, Salmonella spp., Strepococcus suis |
| 04/16/2009 | US20090098157 Helicobacter Pylori Vaccination |
| 04/16/2009 | US20090098155 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |